Navigation Links
Gene expression improves the definition of a breast cancer subtype
Date:12/20/2012

need an additional parameter to help us yet further fine-tune the histopathological diagnosis of Luminal A and B tumours," explains Dr Aleix Prat, leader of the study.

At present, the way of defining luminal or hormone-sensitive tumours is by testing positive to hormone receptors and negative to HER2 expression. The difference between a Luminal A and Luminal B tumour is the amount of Ki-67 protein detected by the pathologist in the tumour cells. If the tumour has fewer than 14% Ki-67-positive cells, it is classified as Luminal A. The problem with this definition of subtype Luminal A is that 30% of these tumours are actually shown as Luminal B by gene expression and hence have an unfavourable prognosis with hormone treatment alone.

A study offering diagnostic improvements

This study checked thousands of tumours from three independent groups from Spain (GEICAM cooperative group, Dr. Martn), Canada (University of British Columbia, Dr. Nielsen) and USA (University of North Carolina, Dr. Perou), to compare whether histopathological data matches the profiles of gene expression, and detected some major discrepancies. Once these differences had been identified, the team sought a new parameter that could be measured in the laboratory to fine-tune the definition. "The genomic study we conducted has shown that the amount of progesterone receptor is important in distinguishing the two biological entities. We can use this new variable as a marker to improve the current histopathological definition of Luminal A tumours," explains Dr Prat. The higher the number of tumour cells that are progesterone-receptor positive, the more likely it is that the diagnosis will be a Luminal A tumour.

The new histopathological definition of Luminal A tumours proposed by this study is "hormone receptor positive, negative HER2 expression, Ki-67-positive lower than 14% and progesterone-receptor positive higher than 20%," specifies Dr Prat.


'/>"/>
Contact: Amanda Wren
awren@vhio.net
34-695-207-886
Vall dHebron Institute of Oncology
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Gene expression test identifies low-risk thyroid nodules
2. Overexpression of proteins 14-3-3 related to chemotherapy resistance
3. Control of gene expression: Histone occupancy in your genome
4. Changes in gene expression may help explain high blood pressure in pregnancy
5. Combination of imaging exams improves Alzheimers diagnosis
6. Palliative care improves outcomes for seniors
7. Metformin improves blood glucose levels and BMI in very obese children
8. New Treatment Aids Weight Loss, Improves Diabetes in Monkeys
9. Networks it takes a village approach improves dementia care and informs research, study shows
10. 1 week at a health spa improves your health, study shows
11. First-of-its-kind program improves outcomes for seniors admitted for trauma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... on October 9, 2007 --, BELLEVILLE, ON, Oct. 5 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc., a ... field trial for its E. coli O157:H7 cattle vaccine,during a: ... & Audio Web Cast ... ...
... million Americans who experience the phantom sounds of tinnitus -- ... debilitating -- certain well-trained rats may be their best hope ... have studied the condition for more than 10 years and ... if they are experiencing tinnitus. , These scientists now have ...
... There are two aspects to creating an effective drug: ... effect and minimal side-effects and then delivering it to ... do its job., With the support from a $478,000, ... Harth is tackling the second part of this problem. ...
... company launches two oncology tests, SAN DIEGO, Oct. ... scheduled to provide a corporate overview of its molecular,diagnostic ... Conference. The presentation is scheduled for Thursday, November,1st, at ... the San Diego Marriott,Del Mar Hotel, 11966 El Camino ...
... 5 GENICON,and SIAD Healthcare S.p.A. announced today the ... SIAD Healthcare S.p.A. has made an,equity investment in GENICON. ... position on GENICON,s Board of Directors, which will be,filled ... August of 2006, GENICON and SIAD Healthcare S.p.A. entered ...
... Governor Edward G. Rendell,today joined the Pennsylvania Dental Association ... in recognizing October 5, 2007,as Senior Smiles Day in ... an individual,s overall,health and quality of life," Rendell said ... million adults over the age of sixty-five reside,in the ...
Cached Medicine News:Health News:Scientists search for brain center responsible for tinnitus 2Health News:Developing a modular, nanoparticle drug delivery system 2Health News:Developing a modular, nanoparticle drug delivery system 3Health News:SIAD Healthcare S.p.A. Acquires Minority Ownership in GENICON 2Health News:Governor Rendell Declares Senior Smiles Day in Pennsylvania; Goal is to Improve Oral Hygiene for Senior Citizens 2
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ... less than 10 bps, yet are surprisingly capable in ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ... as insulin delivery systems especially for type ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... a new market research report is ... Global Markets and Technologies ... Focus on Routes of Administration ... STUDY OBJECTIVES A ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... , THOUSAND OAKS, Calif., Nov. 5 Amgen (Nasdaq: ... PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination ... of metastatic colorectal cancer (mCRC) failed to meet a ... it was announced that the trial met its primary ...
... Partners today announced that it has been engaged by ... help roll out and promote it,s Calmare Therapy Treatment*, ... high-intensity oncologic and neuropathic pain, including pain resistant to ... to expand awareness of the brand and electromedical technology ...
Cached Medicine Technology:Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 2Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 3Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 4Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 5Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 6Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 7Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 8Competitive Technologies Selects RF|Binder as Public Relations Agency of Record 2Competitive Technologies Selects RF|Binder as Public Relations Agency of Record 3
Specimen-ID™, a Positive Specimen Identification System, assures the permanent link at the bedside between patient and laboratory specimen to prevent sample identification errors....
wCareMed™ utilizes barcode scanning technology to support medication administration. It is a simple to use point of care application that provides access to patient information on a lightweight,...
... Korchek Technologies CareChek ... employs barcode technology, Windows ... with integrated scanners (to ... at the bedside) and ...
... SafeRx, in conjunction with the AutoPPI barcoded ... formulated for a specific patient. The system ... to the correct patient and provides printed ... DrugTrack Manager keeps a record of the ...
Medicine Products: